UK's MRC Technology licenses small molecules to Genentech
This article was originally published in Scrip
In the first major small-molecule collaboration between the MRC Technology's Centre for Therapeutics Discovery (CTD) and an industry partner, it has exclusively licensed a series of small-molecule drug candidates for the potential treatment of neurological disease to Genentech (Roche).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.